Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4127 USD | -1.74% | -6.92% | -44.22% |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 9.636 | 6.607 | - | - |
Enterprise Value (EV) 1 | 9.636 | 6.607 | 6.607 | 6.607 |
P/E ratio | -1.19 x | -1.15 x | -1.21 x | -1.2 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | -1.26 x | -0.65 x | -0.55 x | -0.45 x |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 13,023 | 16,008 | - | - |
Reference price 2 | 0.7399 | 0.4127 | 0.4127 | 0.4127 |
Announcement Date | 11/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA 1 | - | -7.631 | -10.1 | -12 | -14.7 |
EBIT 1 | - | -7.633 | -8.215 | -10.24 | -12.7 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -8.357 | -7.968 | -10.06 | -12.43 |
Net income 1 | -6.714 | -8.357 | -7.968 | -10.06 | -12.43 |
Net margin | - | - | - | - | - |
EPS 2 | -0.8500 | -0.6200 | -0.3600 | -0.3400 | -0.3450 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 30/03/23 | 11/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA 1 | - | -1.263 | -1.756 | -2.1 | -2.9 | -3.4 |
EBIT 1 | - | -1.264 | -1.756 | -1.78 | -2.302 | -2.602 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -1.144 | -1.663 | -1.698 | -2.215 | -2.598 |
Net income 1 | -1.036 | -1.144 | -1.663 | -1.698 | -2.215 | -2.598 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.0700 | -0.0500 | -0.1000 | -0.0850 | -0.0900 | -0.1050 |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 09/11/23 | 11/03/24 | 09/05/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex | - | - | - | - | - |
Capex / Sales | - | - | - | - | - |
Announcement Date | 30/03/23 | 11/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.22% | 6.61M | |
+37.74% | 723B | |
+32.22% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+16.60% | 244B | |
+9.77% | 208B | |
-5.15% | 205B | |
+7.43% | 166B |
- Stock Market
- Equities
- CVKD Stock
- Financials Cadrenal Therapeutics, Inc.